Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, announced the closing of a $37 million oversubscribed financing led by Structure Fund. with participation from Meiji Seika Pharma Co., Ltd., Sigmas Group, Kendall Capital Partners, and Patrick and John Collison. Meiji Group holds the No. 1 market share for influenza vaccines in Japan. Patrick Collison is co-founder and CEO of Stripe, Inc.